Regeneron Pharmaceuticals's Revenue
- Regeneron Pharmaceuticals's annual revenue was $14.20 B in fiscal year 2024. The annual revenue increased $1.08 B from $13.12 B (in 2023) to $14.20 B (in 2024), representing a 8.27% year-over-year growth.
- Regeneron Pharmaceuticals's quarterly revenue was $3.68 B in the quarter ending Jun 2025. The quarterly revenue increased $128.50 M from $3.55 B (in Q2: Mar 2024) to $3.68 B (in Q2: Mar 2025), representing a 3.62% year-over-year growth.
- The highest annual revenue for Regeneron Pharmaceuticals was $16.07 B in fiscal year 2021.
- The lowest annual revenue was $4.10 B in fiscal year 2015.
- The average revenue was $9.22 B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2015 - 2024):
Learn more about Regeneron Pharmaceuticals's Revenue by Segment and Revenue by Region.
Check out competitors to Regeneron Pharmaceuticals in a side-by-side comparison.
Explore additional financial metrics for Regeneron Pharmaceuticals.
Definition of Revenue :
Regeneron Pharmaceuticals's Revenue Trend
| 2014 | 2819557000.00 |
|---|---|
| 2015 | 4103728000.00 |
| 2016 | 4860427000.00 |
| 2017 | 5872227000.00 |
| 2018 | 6710800000.00 |
| 2019 | 6557600000.00 |
| 2020 | 8497100000.00 |
| 2021 | 16071700000.00 |
| 2022 | 12172900000.00 |
| 2023 | 13117200000.00 |
| 2024 | 14202000000.00 |
| Mar 2015 | 869612000.00 |
|---|---|
| Jun 2015 | 998617000.00 |
| Sep 2015 | 1137422000.00 |
| Dec 2015 | 1098077000.00 |
| Mar 2016 | 1200849000.00 |
| Jun 2016 | 1212629000.00 |
| Sep 2016 | 1220122000.00 |
| Dec 2016 | 1226827000.00 |
| Mar 2017 | 1318991000.00 |
| Jun 2017 | 1470116000.00 |
| Sep 2017 | 1500673000.00 |
| Dec 2017 | 1582447000.00 |
| Mar 2018 | 1511485000.00 |
| Jun 2018 | 1608022000.00 |
| Sep 2018 | 1663496000.00 |
| Dec 2018 | 1927800000.00 |
| Mar 2019 | 1372600000.00 |
| Jun 2019 | 1577800000.00 |
| Sep 2019 | 1743700000.00 |
| Dec 2019 | 1863500000.00 |
| Mar 2020 | 1828200000.00 |
| Jun 2020 | 1952000000.00 |
| Sep 2020 | 2294000000.00 |
| Dec 2020 | 2422900000.00 |
| Mar 2021 | 2528700000.00 |
| Jun 2021 | 5138500000.00 |
| Sep 2021 | 3452800000.00 |
| Dec 2021 | 4951700000.00 |
| Mar 2022 | 2965100000.00 |
| Jun 2022 | 2857200000.00 |
| Sep 2022 | 2936200000.00 |
| Dec 2022 | 3414400000.00 |
| Mar 2023 | 3162100000.00 |
| Jun 2023 | 3158100000.00 |
| Sep 2023 | 3362700000.00 |
| Dec 2023 | 3434300000.00 |
| Mar 2024 | 3145000000.00 |
| Jun 2024 | 3547100000.00 |
| Sep 2024 | 3720700000.00 |
| Dec 2024 | 3789200000.00 |
| Mar 2025 | 3028700000.00 |
| Jun 2025 | 3675600000.00 |
2024
Regeneron Pharmaceuticals's annual revenue was $14.20 B in fiscal year 2024.
Regeneron Pharmaceuticals's quarterly revenue was $3.15 B(Q1: Mar 2024), $3.55 B(Q2: Jun 2024), $3.72 B(Q3: Sep 2024), $3.79 B(Q4: Dec 2024) in fiscal year 2024.
2023
Regeneron Pharmaceuticals's annual revenue was $13.12 B in fiscal year 2023.
Regeneron Pharmaceuticals's quarterly revenue was $3.16 B(Q1: Mar 2023), $3.16 B(Q2: Jun 2023), $3.36 B(Q3: Sep 2023), $3.43 B(Q4: Dec 2023) in fiscal year 2023.
2022
Regeneron Pharmaceuticals's annual revenue was $12.17 B in fiscal year 2022.
Regeneron Pharmaceuticals's quarterly revenue was $2.97 B(Q1: Mar 2022), $2.86 B(Q2: Jun 2022), $2.94 B(Q3: Sep 2022), $3.41 B(Q4: Dec 2022) in fiscal year 2022.
2021
Regeneron Pharmaceuticals's annual revenue was $16.07 B in fiscal year 2021.
Regeneron Pharmaceuticals's quarterly revenue was $2.53 B(Q1: Mar 2021), $5.14 B(Q2: Jun 2021), $3.45 B(Q3: Sep 2021), $4.95 B(Q4: Dec 2021) in fiscal year 2021.
2020
Regeneron Pharmaceuticals's annual revenue was $8.50 B in fiscal year 2020.
Regeneron Pharmaceuticals's quarterly revenue was $1.83 B(Q1: Mar 2020), $1.95 B(Q2: Jun 2020), $2.29 B(Q3: Sep 2020), $2.42 B(Q4: Dec 2020) in fiscal year 2020.
2019
Regeneron Pharmaceuticals's annual revenue was $6.56 B in fiscal year 2019.
Regeneron Pharmaceuticals's quarterly revenue was $1.37 B(Q1: Mar 2019), $1.58 B(Q2: Jun 2019), $1.74 B(Q3: Sep 2019), $1.86 B(Q4: Dec 2019) in fiscal year 2019.
2018
Regeneron Pharmaceuticals's annual revenue was $6.71 B in fiscal year 2018.
Regeneron Pharmaceuticals's quarterly revenue was $1.51 B(Q1: Mar 2018), $1.61 B(Q2: Jun 2018), $1.66 B(Q3: Sep 2018), $1.93 B(Q4: Dec 2018) in fiscal year 2018.
2017
Regeneron Pharmaceuticals's annual revenue was $5.87 B in fiscal year 2017.
Regeneron Pharmaceuticals's quarterly revenue was $1.32 B(Q1: Mar 2017), $1.47 B(Q2: Jun 2017), $1.50 B(Q3: Sep 2017), $1.58 B(Q4: Dec 2017) in fiscal year 2017.
2016
Regeneron Pharmaceuticals's annual revenue was $4.86 B in fiscal year 2016.
Regeneron Pharmaceuticals's quarterly revenue was $1.20 B(Q1: Mar 2016), $1.21 B(Q2: Jun 2016), $1.22 B(Q3: Sep 2016), $1.23 B(Q4: Dec 2016) in fiscal year 2016.
2015
Regeneron Pharmaceuticals's annual revenue was $4.10 B in fiscal year 2015.
Regeneron Pharmaceuticals's quarterly revenue was $869.61 M(Q1: Mar 2015), $998.62 M(Q2: Jun 2015), $1.14 B(Q3: Sep 2015), $1.10 B(Q4: Dec 2015) in fiscal year 2015.
Regeneron Pharmaceuticals's Revenue (Year-over-Year Change)
| 2014 | 0 |
|---|---|
| 2015 | +45.55 |
| 2016 | +18.44 |
| 2017 | +20.82 |
| 2018 | +14.28 |
| 2019 | -2.28 |
| 2020 | +29.58 |
| 2021 | +89.14 |
| 2022 | -24.26 |
| 2023 | +7.76 |
| 2024 | +8.27 |
| Q1: Mar 15 | 38.97 |
|---|---|
| Q2: Jun 15 | 50.01 |
| Q3: Sep 15 | 56.72 |
| Q4: Dec 15 | 36.86 |
| Q1: Mar 16 | 38.09 |
| Q2: Jun 16 | 21.43 |
| Q3: Sep 16 | 7.27 |
| Q4: Dec 16 | 11.73 |
| Q1: Mar 17 | 9.84 |
| Q2: Jun 17 | 21.23 |
| Q3: Sep 17 | 22.99 |
| Q4: Dec 17 | 28.99 |
| Q1: Mar 18 | 14.59 |
| Q2: Jun 18 | 9.38 |
| Q3: Sep 18 | 10.85 |
| Q4: Dec 18 | 21.82 |
| Q1: Mar 19 | -9.19 |
| Q2: Jun 19 | -1.88 |
| Q3: Sep 19 | 4.82 |
| Q4: Dec 19 | -3.34 |
| Q1: Mar 20 | 33.19 |
| Q2: Jun 20 | 23.72 |
| Q3: Sep 20 | 31.56 |
| Q4: Dec 20 | 30.02 |
| Q1: Mar 21 | 38.32 |
| Q2: Jun 21 | 163.24 |
| Q3: Sep 21 | 50.51 |
| Q4: Dec 21 | 104.37 |
| Q1: Mar 22 | 17.26 |
| Q2: Jun 22 | -44.40 |
| Q3: Sep 22 | -14.96 |
| Q4: Dec 22 | -31.05 |
| Q1: Mar 23 | 6.64 |
| Q2: Jun 23 | 10.53 |
| Q3: Sep 23 | 14.53 |
| Q4: Dec 23 | 0.58 |
| Q1: Mar 24 | -0.54 |
| Q2: Jun 24 | 12.32 |
| Q3: Sep 24 | 10.65 |
| Q4: Dec 24 | 10.33 |
| Q1: Mar 25 | -3.70 |
| Q2: Jun 25 | 3.62 |
2024
Regeneron Pharmaceuticals’s annual revenue increased +8.27% during fiscal year 2024 compared to 2023. It represents a growth of $1.08 B from $13.12 B (in 2023) to $14.20 B (in 2024).
2023
Regeneron Pharmaceuticals’s annual revenue increased +7.76% during fiscal year 2023 compared to 2022. It represents a growth of $944.30 M from $12.17 B (in 2022) to $13.12 B (in 2023).
2022
Regeneron Pharmaceuticals’s annual revenue decreased -24.26% during fiscal year 2022 compared to 2021. It represents a decline of -$3.90 B from $16.07 B (in 2021) to $12.17 B (in 2022).
2021
Regeneron Pharmaceuticals’s annual revenue increased +89.14% during fiscal year 2021 compared to 2020. It represents a growth of $7.57 B from $8.50 B (in 2020) to $16.07 B (in 2021).
2020
Regeneron Pharmaceuticals’s annual revenue increased +29.58% during fiscal year 2020 compared to 2019. It represents a growth of $1.94 B from $6.56 B (in 2019) to $8.50 B (in 2020).
2019
Regeneron Pharmaceuticals’s annual revenue decreased -2.28% during fiscal year 2019 compared to 2018. It represents a decline of -$153.20 M from $6.71 B (in 2018) to $6.56 B (in 2019).
2018
Regeneron Pharmaceuticals’s annual revenue increased +14.28% during fiscal year 2018 compared to 2017. It represents a growth of $838.57 M from $5.87 B (in 2017) to $6.71 B (in 2018).
2017
Regeneron Pharmaceuticals’s annual revenue increased +20.82% during fiscal year 2017 compared to 2016. It represents a growth of $1.01 B from $4.86 B (in 2016) to $5.87 B (in 2017).
2016
Regeneron Pharmaceuticals’s annual revenue increased +18.44% during fiscal year 2016 compared to 2015. It represents a growth of $756.70 M from $4.10 B (in 2015) to $4.86 B (in 2016).
2015
Regeneron Pharmaceuticals’s annual revenue increased +45.55% during fiscal year 2015 compared to 2014. It represents a growth of $1.28 B from $2.82 B (in 2014) to $4.10 B (in 2015).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2024 | $14.20 B | +8.27% |
| 2023 | $13.12 B | +7.76% |
| 2022 | $12.17 B | -24.26% |
| 2021 | $16.07 B | +89.14% |
| 2020 | $8.50 B | +29.58% |
| 2019 | $6.56 B | -2.28% |
| 2018 | $6.71 B | +14.28% |
| 2017 | $5.87 B | +20.82% |
| 2016 | $4.86 B | +18.44% |
| 2015 | $4.10 B | +45.55% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q2: Jun 25 | $3.68 B | 3.62% |
| Q1: Mar 25 | $3.03 B | -3.70% |
| Q4: Dec 24 | $3.79 B | 10.33% |
| Q3: Sep 24 | $3.72 B | 10.65% |
| Q2: Jun 24 | $3.55 B | 12.32% |
| Q1: Mar 24 | $3.15 B | -0.54% |
| Q4: Dec 23 | $3.43 B | 0.58% |
| Q3: Sep 23 | $3.36 B | 14.53% |
| Q2: Jun 23 | $3.16 B | 10.53% |
| Q1: Mar 23 | $3.16 B | 6.64% |
| Q4: Dec 22 | $3.41 B | -31.05% |
| Q3: Sep 22 | $2.94 B | -14.96% |
| Q2: Jun 22 | $2.86 B | -44.40% |
| Q1: Mar 22 | $2.97 B | 17.26% |
| Q4: Dec 21 | $4.95 B | 104.37% |
| Q3: Sep 21 | $3.45 B | 50.51% |
| Q2: Jun 21 | $5.14 B | 163.24% |
| Q1: Mar 21 | $2.53 B | 38.32% |
| Q4: Dec 20 | $2.42 B | 30.02% |
| Q3: Sep 20 | $2.29 B | 31.56% |
| Q2: Jun 20 | $1.95 B | 23.72% |
| Q1: Mar 20 | $1.83 B | 33.19% |
| Q4: Dec 19 | $1.86 B | -3.34% |
| Q3: Sep 19 | $1.74 B | 4.82% |
| Q2: Jun 19 | $1.58 B | -1.88% |
| Q1: Mar 19 | $1.37 B | -9.19% |
| Q4: Dec 18 | $1.93 B | 21.82% |
| Q3: Sep 18 | $1.66 B | 10.85% |
| Q2: Jun 18 | $1.61 B | 9.38% |
| Q1: Mar 18 | $1.51 B | 14.59% |
| Q4: Dec 17 | $1.58 B | 28.99% |
| Q3: Sep 17 | $1.50 B | 22.99% |
| Q2: Jun 17 | $1.47 B | 21.23% |
| Q1: Mar 17 | $1.32 B | 9.84% |
| Q4: Dec 16 | $1.23 B | 11.73% |
| Q3: Sep 16 | $1.22 B | 7.27% |
| Q2: Jun 16 | $1.21 B | 21.43% |
| Q1: Mar 16 | $1.20 B | 38.09% |
| Q4: Dec 15 | $1.10 B | 36.86% |
| Q3: Sep 15 | $1.14 B | 56.72% |
| Q2: Jun 15 | $998.62 M | 50.01% |
| Q1: Mar 15 | $869.61 M | 38.97% |
